Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Da Silva

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Frontiers in Immunology|October 17, 2022
Specific circulating neutrophils subsets are present in clinically stable adults with cystic fibrosis and are further modulated by pulmonary exacerbationsClémence Martin, Théo Dhôte, Maha Zohra Ladjemi, et al.
The European Respiratory Journal|February 8, 2024
Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftorPaul Cazier, Guillaume Chassagnon, Théo Dhote, et al.
Frontiers in Immunology|October 27, 2023
MAIT cells altered phenotype and cytotoxicity in lupus patients are linked to renal disease severity and outcomeElena Litvinova, Carine Bounaix, Guillaume Hanouna, et al.
The European Respiratory Journal|April 23, 2025
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosisPaulette Magnas, Sihem Benaboud, Jennifer Da Silva, et al.
Diagnostic and Interventional Imaging|October 1, 2025
Identification of structural predictors of lung function improvement in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor using deep-learningGuillaume Chassagnon, Rafael Marini, Valentin Ong, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 29, 2021
Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosisPhilippe Reix, Aurélie Tatopoulos, Iulia Ioan, et al.
Clinical Pharmacokinetics|May 22, 2025
Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic FibrosisPaulette Magnas, Naïm Bouazza, Frantz Foissac, et al.
Kidney International|November 10, 2021
Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathyAlexandra Cambier, Patrick J Gleeson, Lilia Abbad, et al.
Nature Communications|July 26, 2020
Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesityAmine Toubal, Badr Kiaf, Lucie Beaudoin, et al.
International Journal of Environmental Health Research|October 21, 2025
The impact of gasoline exposure on telomeres of gas station workers in Rio de JaneiroRafaele Tavares Silvestre, Mariana Chantre Justino, Marcos Massao Murata, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|October 17, 2022
Specific circulating neutrophils subsets are present in clinically stable adults with cystic fibrosis and are further modulated by pulmonary exacerbationsClémence Martin, Théo Dhôte, Maha Zohra Ladjemi, et al.
The European Respiratory Journal|February 8, 2024
Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftorPaul Cazier, Guillaume Chassagnon, Théo Dhote, et al.
Frontiers in Immunology|October 27, 2023
MAIT cells altered phenotype and cytotoxicity in lupus patients are linked to renal disease severity and outcomeElena Litvinova, Carine Bounaix, Guillaume Hanouna, et al.
The European Respiratory Journal|April 23, 2025
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosisPaulette Magnas, Sihem Benaboud, Jennifer Da Silva, et al.
Diagnostic and Interventional Imaging|October 1, 2025
Identification of structural predictors of lung function improvement in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor using deep-learningGuillaume Chassagnon, Rafael Marini, Valentin Ong, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 29, 2021
Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosisPhilippe Reix, Aurélie Tatopoulos, Iulia Ioan, et al.
Clinical Pharmacokinetics|May 22, 2025
Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic FibrosisPaulette Magnas, Naïm Bouazza, Frantz Foissac, et al.
Kidney International|November 10, 2021
Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathyAlexandra Cambier, Patrick J Gleeson, Lilia Abbad, et al.
Nature Communications|July 26, 2020
Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesityAmine Toubal, Badr Kiaf, Lucie Beaudoin, et al.
International Journal of Environmental Health Research|October 21, 2025
The impact of gasoline exposure on telomeres of gas station workers in Rio de JaneiroRafaele Tavares Silvestre, Mariana Chantre Justino, Marcos Massao Murata, et al.
Pageof 5